Effects of simvastatin (20 mg/day) +/- niacin vs simvastatin (80 mg/day) on PCSK9 levels in dyslipidaemic patients with carotid atherosclerosis

Trial Profile

Effects of simvastatin (20 mg/day) +/- niacin vs simvastatin (80 mg/day) on PCSK9 levels in dyslipidaemic patients with carotid atherosclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Dec 2012

At a glance

  • Drugs Niacin (Primary) ; Simvastatin
  • Indications Atherosclerosis; Dyslipidaemias
  • Focus Pharmacodynamics
  • Most Recent Events

    • 02 Dec 2012 New trial record
    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top